GlassScriptPhysician profile
Srinivas Katragadda
NPI 1861483521
$1,213.52
in general payments reported to CMS, 2019-2025
26 companies · $182 in 2025
The $182 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $134 · 2020: $31.84 · 2021: $222 · 2022: $331 · 2023: $261 · 2024: $50.86 · 2025: $182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $494.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $494.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Baxter Healthcare | $138.94 | 2022-2025 | Hillrom - Vest System Model 105 Home Care, Hillrom - Life 2000 Ventilation System |
| Intuitive Surgical, INC. | $97.95 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $81.18 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $69.83 | 2019-2022 | |
| Inogen, INC. | $68.60 | 2022-2025 | Inogen |
| Astellas Pharma US INC | $60.44 | 2021 | |
| Gilead Sciences, INC. | $58.77 | 2021-2022 | |
| Merck Sharp & Dohme LLC | $57.60 | 2021-2023 | Zerbaxa |
| Haemonetics Corporation | $55.65 | 2025 | Teg6s Hemostasis System |
| Jazz Pharmaceuticals INC. | $50.11 | 2022 | |
| Insmed, INC. | $48.82 | 2019-2022 | |
| Glaxosmithkline, LLC. | $43.23 | 2019-2021 | |
| Mylan Specialty L.P. | $41.54 | 2022 | |
| Janssen Biotech, INC. | $40.93 | 2023 | Symtuza |
| Sunovion Pharmaceuticals INC. | $36.63 | 2019 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $33.94 | 2023 | Inspire |
| Pfizer INC. | $33.62 | 2021-2023 | |
| Philips North America LLC | $33.48 | 2023-2025 | Vest Therapy Und |
| Phadia US INC. | $32.39 | 2024 | Immunocap |
| Aimmune Therapeutics, INC. | $23.53 | 2023 | |
| Grifols USA, LLC | $22.71 | 2023 | Prolastin-C Liquid |
| Regeneron Healthcare Solutions, INC. | $21.02 | 2021 | |
| Amgen INC. | $19.63 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $14.95 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $14.26 | 2021 | |
| La Jolla Pharmaceutical Company | $13.77 | 2023 | Xerava |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Srinivas Katragadda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.